Genentech’s Hemlibra Approved for Hemophilia A Patients Without Factor VIII Inhibitors

Genentech snagged a new regulatory approval for its hemophilia treatment, Hemlibra. On Thursday the U.S. Food and Drug Administration approved the medication for hemophilia A patients who do not have factor VIII inhibitors. The approval makes Hemlibra the only prophylactic treatment for people with hemophilia A with and without factor VIII inhibitors that can be administered subcutaneously and … Συνεχίστε να διαβάζετε Genentech’s Hemlibra Approved for Hemophilia A Patients Without Factor VIII Inhibitors.